This unique profile makes OKI-179 promising as a single agent for select hematologic cancers and for use in solid tumors in combination with other targeted therapies, including MEK inhibitors based on a large body of existing literature [14,15,16,17,18]. Here, MAP2K7 is linked to hematopoietic and lymphoid cell neoplasm.